



2121
2IDS
PATENT 9/24/03
15-RI-00501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ting Y. Lee

Serial Number: 10/007,341

Filed: October 25, 2001

For: METHOD AND APPARATUS FOR
CALCULATING BLOOD FLOW
PARAMETERS

Group Art Unit: 2121

Examiner:

RECEIVED

APR 25 2003

Technology Center 2100

RECEIVED

SEP 23 2003

TECHNOLOGY CENTER R3700

CERTIFICATE OF MAILING

I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on April 21, 2003.

Thomas M. Fisher
Thomas M. Fisher, Reg. No. 47,564

INFORMATION DISCLOSURE STATEMENT

1. ☒ Pursuant to 37 CFR 1.97(b)
[within 3 months of filing or prior to 1st Office Action]
2. ☐ Certification Pursuant to 37 CFR 1.97(c)
[before Final Office Action or Allowance]
3. ☐ Fee Payment Pursuant to 37 CFR 1.97(c)
[before Final Office Action or Allowance]
4. ☐ Petition, Certification & Petition Fee Payment Pursuant to 37 CFR 1.97 (d)
[before Issue Fee payment]

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

The following are submitted in the above identified application in compliance with 37 CFR 1.97 & 1.98:

5. ☒ A list of documents on form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.


This Paper is submitted in accordance with:

6. ☒ 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

RECEIVED
APR 30 2003
TECHNOLOGY CENTER 2100

7. ☐ 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
8. ☐ The required certification made in item 11 below; or
9. ☐ The \$180 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
10. ☐ 37 CFR 1.97(d): [before issue fee payment]; and
- ☐ a) This is a petition for consideration of the subject Information Disclosure Statement. The petition fee (\$130.00) required by 37 CFR 1.17(i)(1) is authorized in item 14 below. (Direct this letter to: "Attention GROUP DIRECTOR, and if applicable include batch locator information: e.g., "Allowed Files, Batch _____, Date of Allowance _____"), and
- ☐ b) The required Certification is stated in item 11 below.
11. ☐ Certification
12. ☐ Each item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
13. ☐ No item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this document after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Statement.
14. ☒ Please charge all applicable fees associated with the submittal of this Information Disclosure Statement to Deposit Account No. 01-2384. An original and two copies of this document are enclosed.

Respectfully submitted,



Thomas M. Fisher
Reg. No. 47,564
Armstrong Teasdale LLP
One Metropolitan Square, Suite 2600
St. Louis, MO 63102
(314) 621-5070